462 related articles for article (PubMed ID: 34497419)
21. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
22.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
23. Skewed distribution of TCR V alpha 7-bearing T cells within tumor-infiltrating lymphocytes of HLA-A24(9)-positive patients with malignant glioma.
Ebato M; Nitta T; Yagita H; Sato K; Okumura K
Immunol Lett; 1993 Dec; 39(1):53-64. PubMed ID: 8144191
[TBL] [Abstract][Full Text] [Related]
24. T cell receptor β-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma.
Lu Z; Zhang C; Sheng J; Shen J; Liu B
Int J Cancer; 2017 Jul; 141(2):377-382. PubMed ID: 28431188
[TBL] [Abstract][Full Text] [Related]
25. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
[TBL] [Abstract][Full Text] [Related]
26. Trav15-dv6 family Tcrd rearrangements diversify the Tcra repertoire.
Dauphars DJ; Mihai A; Wang L; Zhuang Y; Krangel MS
J Exp Med; 2022 Feb; 219(2):. PubMed ID: 34910107
[TBL] [Abstract][Full Text] [Related]
27. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
28. The expression profiles of signature genes from CD103
Xia ZA; Lu C; Pan C; Li J; Li J; Mao Y; Sun L; He J
BMC Med; 2023 Jul; 21(1):268. PubMed ID: 37488535
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the T-cell receptor beta chain repertoire in tumor-infiltrating lymphocytes.
Nakanishi K; Kukita Y; Segawa H; Inoue N; Ohue M; Kato K
Cancer Med; 2016 Sep; 5(9):2513-21. PubMed ID: 27465739
[TBL] [Abstract][Full Text] [Related]
31. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
[TBL] [Abstract][Full Text] [Related]
32. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
33. The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Mignon S; Willard-Gallo K; Van den Eynden G; Salgado R; Decoster L; Marien KM; Vansteenkiste JF; Teugels E; De Grève J
Pathol Oncol Res; 2020 Apr; 26(2):1221-1228. PubMed ID: 31228073
[TBL] [Abstract][Full Text] [Related]
34. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
[TBL] [Abstract][Full Text] [Related]
35. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
36. Limited heterogeneity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours.
Ostenstad B; Sioud M; Lea T; Schlichting E; Harboe M
Br J Cancer; 1994 Jun; 69(6):1078-82. PubMed ID: 8198973
[TBL] [Abstract][Full Text] [Related]
37. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer.
Zheng M; Li YM; Liu ZY; Zhang X; Zhou Y; Jiang JL; Zhu P; Yang XM; Tang J; Chen ZN
Front Immunol; 2021; 12():731329. PubMed ID: 35069521
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]